Have the new beta-lactams rendered the aminoglycosides obsolete for the treatment of serious nosocomial infections?
Hospital-acquired infections are often due to multi-resistant gram-negative bacilli. When treating these infections, the physician must use potent antibiotics that have broad spectrums of activity. Aminoglycosidic aminocyclitols and the newer beta-lactam antibiotics are particularly valuable in the management of hospital-acquired infections. This article discusses the role of both classes of antibiotics in this setting.
D000617:Aminoglycosides / Q000627:therapeutic use / Q000633:toxicity; D000900:Anti-Bacterial Agents / Q000627:therapeutic use* / Q000633:toxicity; D001424:Bacterial Infections / Q000188:drug therapy*; D002511:Cephalosporins / Q000627:therapeutic use / Q000633:toxicity; D003428:Cross Infection / Q000188:drug therapy*; D004352:Drug Resistance, Microbial; D006309:Hearing / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins